Atypical Hemolytic Uremic Syndrome Clinical Trials

48 clinical trials for Atypical Hemolytic Uremic Syndrome across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Ravulizumab Outcomes in Polish Patients With aHUS — RECRUITING
• Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS — RECRUITING · PHASE3
• Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) — RECRUITING · PHASE3
• Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS — RECRUITING · PHASE4
• The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt — RECRUITING
• Study of Ultomiris® (Ravulizumab) Safety in Pregnancy — RECRUITING
• Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases — RECRUITING · NA
• A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) — RECRUITING · PHASE3
• Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy — RECRUITING · NA
• Atypical Hemolytic-Uremic Syndrome (aHUS) Registry — RECRUITING
• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford — RECRUITING
• National Registry of Rare Kidney Diseases — RECRUITING
• A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) — RECRUITING · PHASE3
• A PHASE 3, OPEN-LABEL MULTICENTER STUDY OF ALXN1210 IN CHILDREN AND ADOLESCENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) — RECRUITING · PHASE3
• SINGLE ARM STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAIVE ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) — RECRUITING
• OPTIMIZATION OF MAINTENANCE DOSE WITH ECULIZUMAB ACCORDING TO WEIGHT IN PATIENTS WITH ATYPIC HAEMOLITHIC URINE MUSCLE SYNDROME — ACTIVE_NOT_RECRUITING · PHASE4
• Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy — COMPLETED · PHASE3
• A multicenter, single arm, open-label extension study to evaluate the long-term safety, tolerability and efficacy of iptacopan in participants with atypical hemolytic uremic syndrome (aHUS) who have completed a preceding iptacopan phase 3 study in aHUS — TERMINATED · PHASE3
• A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients — ACTIVE_NOT_RECRUITING
• A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) — ACTIVE_NOT_RECRUITING · PHASE3
• A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS) — TERMINATED · PHASE3
• A multicenter, single arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody therapy to iptacopan therapy in study participants with aHUS — TERMINATED · PHASE3
• Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome — TERMINATED · PHASE3
• A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy — OTHER · PHASE3
• Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) — COMPLETED · PHASE3
• Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) — COMPLETED · PHASE3
• Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients — COMPLETED · PHASE2
• A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS) — COMPLETED
• Observational Study of Elizaria® in aHUS Patients — COMPLETED
• Eculizumab to Cemdisiran Switch in aHUS — WITHDRAWN · PHASE2
• Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series — OTHER
• Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment — TERMINATED
• Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS — COMPLETED · PHASE4
• The Role of Microparticles as a Biomarker — WITHDRAWN
• A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome — WITHDRAWN · PHASE2
• TTP and aHUS in Complicated Pregnancies — OTHER
• Complement Inhibition in aHUS Dialysis Patients — TERMINATED · PHASE2
• A PHASE 2, OPEN LABEL, MULTICENTER STUDY OF ALN-CC5 ADMINISTERED SUBCUTANEOUSLY IN ADULT — COMPLETED · PHASE2
• An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome — COMPLETED · PHASE2
• The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) — COMPLETED · PHASE2
• aHUS Observational Long Term Follow-Up — TERMINATED
• Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS — COMPLETED · PHASE2
• Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) — COMPLETED · PHASE2
• Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS — COMPLETED · PHASE2
• Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS — COMPLETED · PHASE2
• An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome — COMPLETED · PHASE2
• To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients — COMPLETED

Refine this search